Wells Fargo & Company MN Has $164.58 Million Holdings in SPDR S&P Biotech ETF (XBI)

Wells Fargo & Company MN raised its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 10.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,716,647 shares of the exchange traded fund’s stock after buying an additional 156,483 shares during the quarter. Wells Fargo & Company MN owned about 2.92% of SPDR S&P Biotech ETF worth $164,576,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. purchased a new stake in shares of SPDR S&P Biotech ETF during the second quarter valued at about $130,000. WP Advisors LLC purchased a new stake in shares of SPDR S&P Biotech ETF during the second quarter valued at about $133,000. Trust Co. of Vermont purchased a new stake in shares of SPDR S&P Biotech ETF during the second quarter valued at about $136,000. Squar Milner Financial Services LLC purchased a new stake in shares of SPDR S&P Biotech ETF during the second quarter valued at about $139,000. Finally, Valeo Financial Advisors LLC lifted its position in shares of SPDR S&P Biotech ETF by 165.2% during the second quarter. Valeo Financial Advisors LLC now owns 1,525 shares of the exchange traded fund’s stock valued at $144,000 after buying an additional 950 shares during the last quarter.

Shares of SPDR S&P Biotech ETF stock opened at $80.78 on Friday. SPDR S&P Biotech ETF has a 52 week low of $76.37 and a 52 week high of $101.55.

ILLEGAL ACTIVITY NOTICE: “Wells Fargo & Company MN Has $164.58 Million Holdings in SPDR S&P Biotech ETF (XBI)” was first published by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/11/10/wells-fargo-company-mn-has-164-58-million-holdings-in-spdr-sp-biotech-etf-xbi.html.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Article: Conference Calls and Individual Investors

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply